Parallel, randomised field efficacy, and return-on-investment study of a next-generation PRRSV2-MLV vaccine compared to a conventional PRRSV1-MLV vaccine in a PRRSV1+2 endemic herd
Collaboration in more than 46 countries.
You are leaving the country website to access another site in the group. Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
SWINE 